HomeNew EGFR Inhibitors

New EGFR Inhibitors

Catalog No. Product Name Information
E1919 Befotertinib mesylate Befotertinib mesylate (D-0316 mesylate) is third-generation tyrosine kinase inhibitor (TKI) of EGFR . It can be used for the research of EGFR T790M-positive non-small cell lung cancer (NSCLC).
E5912 Asandeutertinib Asandeutertinib (Osimertinib-d3, AZD-9291-d3) is an orally administered, ATP-competitive, irreversible, deuterated third-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI) and a deuterium-stabilized derivative of osimertinib, with the potential to treat advanced EGFR-mutated NSCLC.
E5906 Sunvozertinib Sunvozertinib (DZD9008) is an oral, potent, and selective inhibitor of ErbBs (EGFR or Her2), particularly mutant forms of ErbBs. It also inhibits EGFR exon 20 NPH insertion, EGFR exon 20 ASV insertion, EGFR L858R and T790M mutations, Her2 exon 20 YVMA, and EGFR WT A431, with IC50 values of 20.4 nM, 20.4 nM, 1.1 nM, 7.5 nM, and 80.4 nM, respectively.
A4000 Amivantamab (Anti-cMet & EGFR) Amivantamab is a fully human bispecific antibody that targets both epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET). It exhibits immune anticancer activity in non-small cell lung cancer (NSCLC). MW :145.88 KD.
E4664 Osimertinib dimesylate Osimertinib dimesylate (Mereletinib dimesylate, AZD-9291 dimesylate) is a potent, mutant-selective, irreversible inhibitor of EGFR kinase activity with an IC50s of 12 and 1 nM against EGFRL858R and EGFRL858R/T790M, respectively. It demonstrates anti-tumor activity in xenograft and transgenic T790M EGFR mutant models, supporting its use in non-small cell lung cancer (NSCLC) research.
≡ All EGFR Inhibitors